The authors concluded that a therapeutic strategy of expanding CD4+CD25highFoxP3+ in humans may be harmful via the augmentation of Th2 immune responses in patients with idiopathic pulmonary fibrosis and other fibroproliferative lung diseases. The gene discussed is CD4; the disease is pulmonary fibrosis.